Oncocyte (NASDAQ:IMDX – Get Free Report)‘s stock had its “equal weight” rating restated by equities research analysts at Stephens in a report released on Wednesday, Benzinga reports. They presently have a $4.00 price target on the stock. Stephens‘s price objective would indicate a potential upside of 124.72% from the company’s previous close.
Several other research analysts have also weighed in on IMDX. Wall Street Zen lowered Oncocyte from a “hold” rating to a “sell” rating in a report on Saturday, October 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Oncocyte in a report on Monday, September 21st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $9.00 price target on shares of Oncocyte in a research report on Tuesday, August 18th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $8.33.
View Our Latest Research Report on IMDX
Oncocyte Price Performance
Shares of IMDX stock opened at $1.78 on Wednesday. Oncocyte has a 12-month low of $1.63 and a 12-month high of $7.51. The firm has a fifty day moving average of $3.20 and a 200-day moving average of $4.50.
Oncocyte (NASDAQ:IMDX – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.19) EPS for the quarter. The company had revenue of $0.56 million for the quarter.
Oncocyte Company Profile
Oncocyte Corporation, now known as Insight Molecular Diagnostics, Inc. (NASDAQ: IMDX), is a molecular diagnostics company focused on monitoring organ transplants. Its tests analyze donor-derived cell-free DNA in a transplant recipient’s blood to help assess graft health and identify signs of potential injury or rejection. The company’s VitaGraft tests include assays for kidney and liver transplant monitoring. These laboratory-developed tests are processed through the company’s clinical laboratory and are intended to provide clinicians with information that can complement other aspects of post-transplant care.
Read More
- Five stocks we like better than Oncocyte
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
Receive News & Ratings for Oncocyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncocyte and related companies with MarketBeat.com's FREE daily email newsletter.
